, Tracking Stock Market Picks
Enter Symbol:
Rating: AVII
Buy $55

Sarepta Therapeutics Inc (NASDAQ: SRPT) reiterated to Buy with price target $55 by Needham

Friday,  Oct 2, 2015  3:25 PM ET by Kristen Bailey

Needham reiterated Sarepta Therapeutics Inc (NASDAQ: SRPT) to Buy with price
target $55. Needham rated Sarepta Therapeutics Inc (NASDAQ: SRPT) to Buy with price target $38 on 03/02/2015, when the price was $13.88.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy